Lung Cancer Treatments and Mutations

TopicLeading institutions, researchers & key papers

This cluster of papers focuses on the advancements in lung cancer research, particularly in understanding EGFR and ALK mutations, targeted therapy, resistance mechanisms to tyrosine kinase inhibitors, clinical trials evaluating different treatment regimens, genomic profiling for personalized medicine, and the development of treatment guidelines based on molecular biomarkers. The research also explores the concept of oncogene addiction and its implications for targeted therapies.

1,269

Works

IDs:OpenAlex

How has Lung Cancer Treatments and Mutations's publication output changed over time?

ScholarIQpublication output · 2005–2018

Output declined67% over the shown period — from 3 works in 2005 to 1 in 2018.

2005200620072009201020112012201320172018

What are the most-cited papers on Lung Cancer Treatments and Mutations?

ScholarIQmost cited works

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J. Kaye, Neal I. Lindeman, Titus J. Boggon, Katsuhiko Naoki, Hidefumi Sasaki, Yoshitaka Fujii, Michael J. Eck, William R. Sellers, Bruce E. Johnson, Matthew Meyerson

Science. 20049,435 Citations

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin-Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma Duffield, Claire Watkins, Alison Armour, Masahiro Fukuoka

New England Journal of Medicine. 20098,284 CitationsOPEN ACCESS

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Alan Sandler, Robert J. Gray, Michael C. Perry, Julie R. Brahmer, Joan H. Schiller, Afshin Dowlati, Rogério Lilenbaum, David H. Johnson

New England Journal of Medicine. 20065,784 CitationsOPEN ACCESS

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais, A. Vergnenègre, Bartomeu Massutí, Enriqueta Felip, Ramón Palmero, Ramón García-Gómez, Cinta Pallarés, José Miguel Sánchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Morán, Amelia Insa, Filippo de Marinis, R. Corre, Isabel Bover, Alfonso Illiano, Éric Dansin, Javier de Castro, Michèle Milella, Noemı́ Reguart, Giuseppe Altavilla, Ulpiano Jiménez, Mariano Provencio, Miguel Ángel Moreno, Josefa Terrasa, José Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Dómine, Olivier Molinier, Julien Mazières, Nathalie Baize, Rosario García‐Campelo, G. Robinet, Delvys Rodríguez‐Abreu, Guillermo López-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, P. Bombaron, Reyes Bernabé, Alessandra Bearz, Á. Artal, Enrico Cortesi, Christian Rolfo, María Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, José Luis Ramírez, José Javier Sánchez, Miguel Ángel Molina‐Vila, Miquel Tarón, Luis Paz‐Ares

The Lancet Oncology. 20125,545 CitationsOPEN ACCESS

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel Campos, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano Van Kooten, Mircea Dediu, B. Findlay, Dongsheng Tu, D. Johnston, Andrea Bezjak, Gary M. Clark, P. Santabárbara, Lesley Seymour

New England Journal of Medicine. 20055,459 CitationsOPEN ACCESS